*QIAGEN ENHANCES LEADING CLINICAL GENOMICS PORTFOLIO WITH ACQUISITION OF GENOOX AI-POWERED SOFTWARE
*QIAGEN NV - ACQUISITION IS EXPECTED TO GENERATE APPROXIMATELY $5 MLN OF SALES IN 2025 FOR QIAGEN AND HAVE A NEUTRAL IMPACT ON ADJUSTED EPS
*QIAGEN NV - ACQUIRES GENOOX FOR $70 MILLION PLUS $10 MILLION IN MILESTONES
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 12-MAY-202520:05:00.243 GMT